SNS Financial Group LLC Cuts Stock Position in Pfizer Inc. (NYSE:PFE)

SNS Financial Group LLC reduced its position in Pfizer Inc. (NYSE:PFE) by 8.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,984 shares of the biopharmaceutical company’s stock after selling 1,140 shares during the quarter. SNS Financial Group LLC’s holdings in Pfizer were worth $344,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of PFE. Wells Trecaso Financial Group LLC lifted its stake in shares of Pfizer by 2.5% in the 3rd quarter. Wells Trecaso Financial Group LLC now owns 14,361 shares of the biopharmaceutical company’s stock valued at $416,000 after acquiring an additional 350 shares during the last quarter. Washington Trust Advisors Inc. lifted its stake in shares of Pfizer by 0.7% in the 3rd quarter. Washington Trust Advisors Inc. now owns 49,216 shares of the biopharmaceutical company’s stock valued at $1,424,000 after acquiring an additional 360 shares during the last quarter. PSI Advisors LLC lifted its stake in shares of Pfizer by 1.4% in the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock valued at $738,000 after acquiring an additional 385 shares during the last quarter. Western Pacific Wealth Management LP lifted its stake in shares of Pfizer by 10.5% in the 3rd quarter. Western Pacific Wealth Management LP now owns 4,073 shares of the biopharmaceutical company’s stock valued at $118,000 after acquiring an additional 386 shares during the last quarter. Finally, Waddell & Associates LLC lifted its stake in shares of Pfizer by 1.6% in the 3rd quarter. Waddell & Associates LLC now owns 24,978 shares of the biopharmaceutical company’s stock valued at $723,000 after acquiring an additional 388 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Up 1.2 %

Shares of NYSE:PFE opened at $25.87 on Thursday. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The firm has a market capitalization of $146.58 billion, a P/E ratio of 18.34, a P/E/G ratio of 0.63 and a beta of 0.64. The stock has a 50 day moving average price of $26.28 and a 200-day moving average price of $27.45. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the prior year, the company earned $0.10 EPS. The business’s revenue was up 24.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.65%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is presently 121.99%.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent research reports. Evercore ISI raised Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. Bank of America reaffirmed a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Guggenheim reaffirmed a “buy” rating and set a $33.00 price target on shares of Pfizer in a research report on Monday, February 10th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.